Navigation Links
Iomai CEO to Speak at Acumen BioFin Rodman & Renshaw Annual Healthcare Conference on Monday, Nov. 5
Date:11/2/2007

GAITHERSBURG, Md., Nov. 2 /PRNewswire-FirstCall/ -- Iomai Corporation (Nasdaq: IOMI) today announced that Stanley C. Erck, the company's president and chief executive officer, will present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference in New York City on Monday, Nov. 5. Mr. Erck's presentation will begin at 9:10 a.m. Eastern Time in the Kennedy I Room of the New York Palace Hotel.

Mr. Erck's presentation will focus on Iomai's portfolio of patch-based needle-free vaccines and immunostimulants, including its plans to move into Phase 3 trials for its travelers' diarrhea vaccine and the initiation of a Phase 1/2 trial of Iomai's dose-sparing adjuvant patch for use with a pandemic influenza vaccine.

To access the live audio webcast or the subsequent archived recording, log on to the Investor Relations section on the Overview page of the Iomai website at http://www.iomai.com. Please connect to Iomai's website several minutes prior to the start of the live webcast to ensure adequate time for any software downloads that may be necessary.

ABOUT IOMAI CORPORATION

Iomai Corporation discovers and develops vaccines and immune system stimulants, delivered via a novel, needle-free technology called transcutaneous immunization (TCI). TCI, discovered by researchers at the Walter Reed Army Institute of Research, taps into the unique benefits of a major group of antigen-presenting cells found in the outer layers of the skin (Langerhans cells) to generate an enhanced immune response. Iomai is leveraging TCI to enhance the efficacy of existing vaccines, develop new vaccines that are viable only through transcutaneous administration and expand the global vaccine market. Iomai currently has four product candidates in development: three targeting influenza and pandemic flu and one to prevent travelers' diarrhea. For more information on Iomai, please visit http://www.iomai.com.


'/>"/>
SOURCE Iomai Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Iomai to Announce Results From Phase 1 Influenza Trial and Host Webcast Tomorrow
2. Iomai Dose-Ranging Trial Demonstrates Needle-Free Patch Vaccine for Travelers Diarrhea Stimulates Immune Response Even at Low Doses
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
5. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
6. Micromet, Inc. to Present at the 3rd Annual C.E. Unterberg, Towbin Emerging Growth Conference
7. Neurologix to Present at the Third Annual C.E. Unterberg Towbin Emerging Growth Conference
8. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
9. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
10. MaxCyte and Medinet to Present at the 13th Annual Meeting of the International Society for Cellular Therapy (ISCT) in Sydney, Australia
11. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... -- Trifecta Clinical , a leading global provider ... Ward to Vice President of Commercial Operations.  Rick ... the promotion of Ericka Atkinson to Vice ... joins Trifecta from Greenphire where he was Vice President ... positions within the healthcare industry throughout his career.  "Rick ...
(Date:1/24/2017)... Results show Gamma Knife spares normal brain tissue ... Elekta (EKTA-B.ST) today announced new data demonstrating ... a higher radiation dose compared to linear accelerator (linac)-based delivery ... complex brain tumors, were published in the Journal ... ...
(Date:1/24/2017)... , January 24, 2017 www.Financialbuzz.com ... growing industries in the United States ... in 2016. In addition, Proposition 64, the California Cannabis Legalization ... 42.87% against on November 8, 2016. This outcome means that ... use and to grow a certain amount of cannabis for ...
Breaking Medicine Technology:
(Date:1/24/2017)... ... January 24, 2017 , ... West’s Health Advocate ... Solutions Series of webinars will start January 31 with a session about understanding ... current health and benefits topics, including employee engagement, pricing transparency, population health and ...
(Date:1/24/2017)... ... 24, 2017 , ... This Saturday, January 28, the BCFA presents more than ... by Alabama Symphony Orchestra musicians Yifan Zhou, Mara McClain & Sarah Nordlund Dennis. Local ... exhibitors offer a look at Chinese games, crafts & more. Festivities begin at 11:00 ...
(Date:1/24/2017)... ... January 24, 2017 , ... The NewKILO JRP, a three-year project ... co-funded by the European Union (EU), was completed in May 2015. The future definition ... maintained and used in air, which presents some challenges to establishing traceability to the ...
(Date:1/24/2017)... ... January 24, 2017 , ... TopConsumerReviews.com recently gave a ... premenstrual syndrome, or PMS . , Most women of child-bearing age will experience ... constipation, irritability, headaches, fatigue, and other discomfort. For some women, the effects ...
(Date:1/24/2017)... ... ... “Mysteries Revealed On Speaking In Tongues”: an engaging and dynamic study on what ... On Speaking In Tongues” is the creation of published author, Tina Jackson, the editor, ... , “We need to partner with Jesus and be the voice piece to ...
Breaking Medicine News(10 mins):